Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1772P - Impact assessment of SARS-CoV-2 testing on cancer patients undergoing immunosuppressive treatment


17 Sep 2020


E-Poster Display


COVID-19 and Cancer

Tumour Site


Alda Tavares


Annals of Oncology (2020) 31 (suppl_4): S934-S973. 10.1016/annonc/annonc289


A. Tavares1, D. Magalhães1, A. Soares1, J. Laranjinha2, A. Mesquita1, F. Duarte2, R.C. Abreu2, H. Magalhães1, F. Braga1, C. Sottomayor1, M. Salgado1

Author affiliations

  • 1 Department Of Medical Oncology, Hospital Pedro Hispano, Matosinhos Local Health Unit, 4464-513 - Senhora da Hora/PT
  • 2 Department Of Infectious Diseases, Hospital Pedro Hispano, Matosinhos Local Health Unit, 4464-513 - Senhora da Hora/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1772P


On March 11, 2020, COVID-19 was declared a global pandemic. Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this infection may remain asymptomatic. The European Society of Medical Oncology and the Portuguese Health Authority recommended both a symptomatic survey and laboratory testing in all cancer patients (pts) undergoing immunosuppressive treatment (IT). The impact of this measure is still unknown. We report our experience in a Portuguese center.


Since March 2020, a symptomatic survey has been performed at our institution before each hospital visit. From April 6 through May 8, 2020, reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 testing was added on cancer pts before undergoing IT. The impact of this intervention was evaluated comparing the hospitalization rate of cancer pts due to COVID-19, before and after the introduction of RT-PCR testing. Retrospective analysis of clinical data was performed.


444 tests were carried out on 244 pts and laboratory SARS-CoV-2 infection was confirmed in 11 (5%); 5 were male, with a median age of 65 years [34-76]. Breast and colorectal cancer were prevalent; 2 pts had lung cancer; 6 advanced disease. Ongoing IT in these pts was temporarily suspended: 9 pts under chemotherapy, 1 atezolizumab and 1 rituximab. Only 1 patient was symptomatic (9%) and previously hospitalized. No admission due to COVID-19 was registered in this group. Since March 7, 179 pts were admitted due to COVID-19 at our center: 12 were active cancer pts (6.7%) of which 4 were under IT. 6 of the oncological pts passed away, all of them had advanced diseases, 1 was under IT. Of the dead pts, lung and breast tumors were prevalent. Among all COVID-19 hospitalizations, the prevalence of pts under IT was similar before and after the implementation of the RT-PCR testing (2.2% vs. 2.4%).


We found a significant percentage of active cancer pts diagnosed with asymptomatic COVID-19. Due to the small sample size of COVID-19 pts under IT, it is difficult to evaluate the impact of RT-PCR testing. However, on a long-term analysis, this intervention may reduce the risk of severe complications related to COVID-19 in cancer pts. Health education and dynamic organization are also important measures.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.